Dear editor, Pancreatic cancer (PC) is the fourth most common cause of cancer-related mortality, with a meager 5-year survival rate of under 20%. 1 Patients with PC often exhibit nonspecific symptoms such as abdominal pain and weight loss, leading to delayed diagnosis. However, even when promptly diagnosed after symptom onset, the majority of PC patients are found to have advanced-stage disease. Despite notable progress in surgical methods, chemotherapy, and radiation therapy, the 5-year survival rate remains dishearteningly low at 8.2%. 2While the exact causes of PC remain poorly understood, several risk factors have been identified. These include a family history of PC, obesity, chronic pancreatitis (CP), smoking, the presence of preneoplastic lesions, or certain hereditary syndromes associated with a high risk of developing PC. 3 Cross-sectional imaging is a vital tool in initially assessing symptomatic individuals suspected of having PC. It is also crucial in screening asymptomatic individuals at a heightened risk of developing PC. 4 Computed tomography (CT) is the predominant imaging diagnostic method, often complemented by endoscopic ultrasound with fine needle biopsy or aspiration for pinpointing small lesions and confirming diagnoses definitively. 5 Additionally, magnetic resonance imaging (MRI) and positron emission tomography (PET) play significant roles in systematically staging the disease and determining whether the primary tumor is resectable, borderline resectable, or unresectable. 5 Radiomics, a subset of medical imaging, involves extracting quantitative data from various medical images like CT scans, MRI scans, or PET scans. This data is then meticulously analyzed to glean valuable insights into tumor heterogeneity. 6 Quantitative imaging facilitates integrating radiomics and dynamic imaging features, independently or together, enabling the construction of clinical prediction models.